Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment

Epigenetic mechanisms are implicated in transcriptional programs driving chronic kidney disease (CKD). Apabetalone is an orally available inhibitor of bromodomain and extraterminal (BET) proteins, which are epigenetic readers that modulate gene expression. In the phase 3 BETonMACE trial, apabetalone...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilham, Dean, Wasiak, Sylwia, Rakai, Brooke D., Fu, Li, Tsujikawa, Laura M., Sarsons, Christopher D., Carestia, Agostina, Lebioda, Kenneth, Johansson, Jan O., Sweeney, Michael, Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295623/
https://www.ncbi.nlm.nih.gov/pubmed/37371758
http://dx.doi.org/10.3390/biomedicines11061663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295623/
https://www.ncbi.nlm.nih.gov/pubmed/37371758
http://dx.doi.org/10.3390/biomedicines11061663

Ejemplares similares